Free Access
Tableau II.
Nombre d’accords passés par 30 des firmes impliquées dans le domaine des anticorps à usage thérapeutique. Accords: fusions, acquisitions, partenariats.
| Entreprises | Nombre d’accords | Entreprises | Nombre d’accords |
|---|---|---|---|
| Janssen Biotech Inc | 11 | Alexion Pharmaceuticals | 5 |
| Merck & Co Inc | 11 | Amgen Inc | 5 |
| Novartis AG | 9 | Biogen Inc | 5 |
| AbbVie Inc | 8 | Emergent BioSolutions Inc | 5 |
| Bristol-Myers Squibb Co | 8 | MorphoSys AG | 5 |
| Celgene Corp | 7 | Xencor Inc | 5 |
| Eli Lilly and Co | 7 | ADC Therapeutics SA | 4 |
| F. Hoffmann-La Roche Ltd | 7 | Astellas Pharma Inc | 4 |
| GlaxoSmithKline Plc | 7 | Kiniksa Pharmaceuticals | 4 |
| Sanofi | 7 | Laboratoires Servier | 4 |
| Agenus Inc | 6 | Ligand Pharmaceuticals Inc | 4 |
| Gilead Sciences Inc | 6 | Shire Plc | 4 |
| MedImmune LLC | 6 | Sorrento Therapeutics Inc | 4 |
| Pfizer Inc | 6 | Zai Lab Ltd | 4 |
| Takeda Pharmaceutical Ltd | 6 | Zymeworks Inc | 4 |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.